Y mAbs Therapeutics — Corporate Update (January 2024)
25 slides from Y mAbs Therapeutics's corporate update, Jan 9, 2024
Slide 1: Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody-based Therapies
Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody - based Therapies January 2024
Slide 2: Disclaimer
Disclaimer Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of t
Slide 3: Strongly Positioned to Drive Future Value
Strongly Positioned to Drive Future Value 3 Novel Platforms in Development S elf - A ssembly D is A ssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT ”) Monoclonal Antibodies GD2 - SADA Phase I Part A Data Readout CD38 - SADA Phase I Study Initiation MSK Data Readout of Phase II Osteos
Slide 4: Advancing Focused Pipeline with Multiple Value-Added Catalysts Ahead
Advancing Focused Pipeline with Multiple Value - Added Catalysts Ahead 4 Study Therapeutic Area Preclinical Phase I Phase II/Pivotal Approved Trial Sponsor Status Lead Programs 201 Relapsed/Refractory High - Risk Neuroblastoma (Pediatric) U.S. FDA approved Naxitamab - gqgk (Anti - GD2) 12 - 230 Rela
Slide 5: Novel SADA Pretargeted Radioimmunotherapy Technology Platform
5 Novel SADA Pretargeted Radioimmunotherapy Technology Platform
Slide 6: Current Radiopharma Challenges Negatively Impact Patient Care
Current Radiopharma Challenges Negatively Impact Patient Care 6 Infrastructure and Manufacturing Physician Participation Administration Sites Continuing Drug Shortages Simpler, more user - friendly solutions greatly needed for physicians and patients
Slide 7: SADA's Novel Pretargeted-Step Approach a Potential Industry Game-Changer
SADA’s Novel Pretargeted 2 - Step Approach a Potential Industry Game - Changer * 7 Novel SADA Platform Potential Capabilities x Pretargeting tumor potentially minimizes toxicity and potentially enhances rapid clearing of unbound protein x Potential to work with short T 1/2 isotopes x Potentially bro
Slide 8: Self-Assembly Disassembly (SADA) Technology
S elf - A ssembly D is A ssembly (SADA) Technology: High Affinity for Tumor Targets and Rapid Clearance from Blood Stream SADA domains uniquely selected to allow proteins to change size based on concentration Adapted from Santich et al. Clin Canc Res 2020 S elf - A ssembled Tetramer ~200 kDa Strong
Slide 9: Conventional GD2 Antibody's Persistence in Blood Stream Leads to Unwanted Exposure
Conventional GD2 Antibody’s Persistence in Blood Stream Leads to Substantial Unwanted Exposure and Increased Toxicity 9 Adapted from Santich et al. Clin Canc Res 2021 Blood E xposure (Radioactive P ayload ) 1. IgG Bispecific 2. DOTA Time Concentration (Radioactive Payload) Tumor
Slide 10: GD2-SADA Achieves High Tumor Uptake with Minimal Exposure to Other Tissues
GD2 - SADA Achieves High Tumor Uptake with Minimal Exposure to All Other Tissues 10 Blood E xposure (Radioactive Payload) 1. IgG Bispecific 2. DOTA 1. SADA Bispecific 2. DOTA Concentration (Radioactive Payload) Tumor Tumor U ptake (Radioactive P ayload ) Adapted from Santich et al. Clin Canc Res 202
Slide 11: Study 1001: GD2-SADA Ongoing Phase I Clinical Trial
Part A N = 15 - 18 › GD2 – SADA protein dose escalation from 0.3 mg/kg to 10 mg/kg with fixed therapeutic 177 Lu - DOTA dose of 200 mCi (7.4 GBq) – interval between SADA and payload to be explored Part B N = 9 - 12 › 177 Lu - DOTA therapeutic dose escalation from 400 mCi (14.8 GBq) to 750 mCi (27.8
Slide 12: Study 1001: SPECT/CT Scan Demonstrating Tumor Binding of Lu-GD2 SADA
Study 1001: SPECT/CT Scan Demonstrating Tumor Binding of 177 Lu - GD2 SADA * • Example of tumor targeting in Osteosarcoma using 177 Lu - DOTA dose of 30 mCi (imaging dose) in patient • Arrow indicates tumor metastasis located in the Thoracic cavity – with 177 Lu - DOTA uptake • Scan performed 24 hou
Slide 13: Study 1001: SPECT/CT Scan on Osteosarcoma Patient Demonstrating Positive Tumor Uptake
Study 1001: SPECT/CT Scan on Osteosarcoma Patient Demonstrating Positive Tumor Uptake After Exposure * • Patient treated with 0.3 mg/kg GD2 - SADA, followed by 200 mCi 177 Lu - DOTA (lowest therapeutic radionuclide dose) 48 - hours later • Scan performed 24 hours after radionuclide administration •
Slide 14: Ongoing GD2-SADA Phase I Trial: Initial PK Data
Ongoing GD2 - SADA Phase I Trial: Initial PK Data * 14 Non - QC data 0 20 40 60 80 100 120 140 GD2 - SADA conc Hours *These early results are not complete and are not necessarily indicative of the full results or ultimate success of the SADA tri als or the SADA development program. Limitation: Patie
Slide 15: Novel SADA Platform Potentially Provides Simplicity and Enhanced Precision
15 Novel SADA Platform Potentially Provides Simplicity and Enhanced Precision for Physicians and Patients * › Additional early - stage programs include: › HER2 - SADA › B7H3 - SADA Ongoing GD2 - SADA Phase I Trial (Study 1001) › Evidence of tumor update › No DLTs or pain observed to date › Demonstra
Slide 16: Planned CD38-SADA Phase I Clinical Trial (Study 1201): Study Design
Part A N = 12 - 15 › CD38 - SADA dose escalation with fixed imaging and therapeutic 177 Lu - DOTA doses Part B N = 12 - 15 › 177 Lu - DOTA therapeutic dose escalation with the CD38 - SADA dose determined in Part A Part C N = 20 › Repeated dosing up to 6 cycles Planned CD38 - SADA Phase I Clinical Tr
Slide 17: Commercial Progress DANYELZA: GD2 Antibody for R/R High-Risk Neuroblastoma
17 Commercial Progress DANYELZA® ( naxitamab - gqgk ): GD2 Antibody for R/R High - Risk Neuroblastoma
Slide 18: Solid Drivers of Market Uptake
Solid Drivers of Market Uptake • New DANYELZA campaign rolled out in Q4 2023 • 167 new patient starts to date since 2021 launch • Increasing share of U.S. anti - GD2 market with 17% ** DANYELZA: Only FDA - Approved Medicine for R/R NB Patients 18 Neuroblastoma • NB forms in certain types of nerve ti
Slide 19: Prespecified Interim Analysis: Waterfall Plot of Change in Curie Score
Study 201 Prespecified Interim Analysis: Waterfall Plot of Change in Curie Score in all Relapsed/Refractory Patients with Bone Disease (n = 48) Adapted from: Kushner B, et al. Poster presented at ESMO - IO; Geneva, Switzerland; December 6 - 8, 2023 19
Slide 20: Ongoing Naxitamab Clinical Trials
Ongoing Naxitamab Clinical Trials • Phase II BCC multi - center trial evaluating naxitamab + standard induction therapy in patients with newly diagnosed High - Risk Neuroblastoma • 13 sites initiated; target 40 - 50 sites in U.S. and Canada • 6 patients dosed; target 76 total patients • Multi - cent
Slide 21: Ongoing and Potential New Studies for Naxitamab: Expanding Usage in New Indications
Ongoing and Potential New Studies for Naxitamab : Expanding Usage in New Indications Cancer Indications T reatable Patient Population (U.S.) GD2 E xpression High - Risk Neuroblastoma Relapsed / Refractory 300 ~ 99 - 100% Front - line Induction 450 Osteosarcoma Relapsed/ R ecurrent 200 ~ 88% Soft - T
Slide 22: DANYELZA Addresses Significant Unmet Needs in R/R High-Risk NB
22 DANYELZA Addresses Significant Unmet Needs in R/R High - Risk NB with Expansion Potential Across Broader Patient Populations U.S. commercialization in high - risk NB. Launch in China by SciClone; LATAM partner Adium ; EU access via WEP Studies 12 - 230 and 201 formed primary basis of approval in
Slide 23: Company Takeaways
NZ -mAbs Ng Therapeutics, Inc. Company Takeaways
Slide 24: Strongly Positioned to Drive Future Value
Strongly Positioned to Drive Future Value 24 Novel Platforms in Development S elf - A ssembly D is A ssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT ”) Monoclonal Antibodies GD2 - SADA Phase I Part A Data Readout CD38 - SADA Phase I Study Initiation MSK Data Readout of Phase II Osteo
Slide 25: Thank You
THANK YOU
Y-mAbs Therapeutics — Corporate Update (January 2024) on 6ix